Eyenovia (NASDAQ:EYEN) Trading Up 7.4%

Eyenovia, Inc. (NASDAQ:EYEN) shares were up 7.4% on Thursday . The company traded as high as $6.30 and last traded at $6.06. Approximately 384,817 shares changed hands during trading, a decline of 2% from the average daily volume of 393,230 shares. The stock had previously closed at $5.64.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Eyenovia from a “hold” rating to a “sell” rating in a research report on Friday. Roth Capital dropped their target price on shares of Eyenovia from $14.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price (down previously from $7.00) on shares of Eyenovia in a report on Friday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Eyenovia has an average rating of “Hold” and a consensus price target of $9.94.

The firm’s fifty day simple moving average is $4.23 and its 200 day simple moving average is $3.61. The firm has a market cap of $150.80 million, a P/E ratio of -5.51 and a beta of 2.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.77 and a current ratio of 3.77.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.05). On average, equities research analysts predict that Eyenovia, Inc. will post -0.99 earnings per share for the current year.

In other Eyenovia news, major shareholder Stuart M. Grant bought 100,000 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were purchased at an average cost of $3.55 per share, for a total transaction of $355,000.00. Following the transaction, the insider now owns 4,169,748 shares of the company’s stock, valued at $14,802,605.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 23.50% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. National Asset Management Inc. purchased a new stake in Eyenovia in the 3rd quarter worth about $41,000. Virtu Financial LLC purchased a new stake in Eyenovia in the 3rd quarter worth about $51,000. Shone Asset Management LLC purchased a new stake in Eyenovia in the 3rd quarter worth about $69,000. Finally, BlackRock Inc. raised its position in Eyenovia by 11.9% in the 3rd quarter. BlackRock Inc. now owns 49,255 shares of the company’s stock worth $153,000 after purchasing an additional 5,257 shares during the period. 6.32% of the stock is currently owned by institutional investors.

Eyenovia Company Profile (NASDAQ:EYEN)

Eyenovia, Inc, a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments.

See Also: Stock Symbols and CUSIP Explained

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.